Diabetes

 

Updated glucose-lowering therapy guidance issued amid national shortage of GLP-1 receptor agonists

This updated document was produced by the Association of British Clinical Diabetologists in support of ongoing national shortage of glucagon like peptide-1 receptor agonists (GLP1 RA agents) used in the management of type 2 diabetes. The situation is not expected to resolve until late 2024. Therefore, this document is aimed to support primary care teams in selecting appropriate antidiabetic agent alternatives if a GLP1 RA a type 2 diabetes patient is taking becomes unavailable. This document is outside the scope of use of GLP1 Ras for the management of obesity.

Please see updated guidance from April 2024 here.

 

Lincolnshire Blood Glucose and Ketone test strips FormularyBlood Glucose.PNG

This guidance is an updated formulary for blood glucose and ketone test strips. It was produced by the Lincolnshire Diabetes Specialist Clinicians and Lincolnshire ICB Medicines Optimisation Team, and approved at PACEF September 2023. It is based on the NHS England Commissioning National Recommendations produced April 2023.

It provides guidance on appropriate, cost effective blood glucose meters, test strips and ketone test strips.

 

Full Guidance Here

 

Supply DisruptionDiabetes.png

There is an ongoing national shortage of glucagon like peptide-1 receptor agonists (GLP-1 RAs). This is our guidiance on how to navigate through this shortage. 

Click here for the full guidance

Semaglutide (Wegovy®) - Position StatementSemaglutide Position Statement.PNG

Lincolnshire ICB have issues a position statement on the use of Semaglutide for managing overweight and obesity. 

Click on the image for the full statement

Selecting alternative glucose-lowering therapy when GLP-1 RAs are unavailable

Diabetes Continuous Glucose Monitoring (CGM)

The Lincolnshire Integrated Care Board Interim Position Statement on CGM can be found here.